MedPath

New Epsilon Innovation Limited

🇭🇰Hong Kong, China
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:1
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia

Phase 1
Active, not recruiting
Conditions
Relapsed AML
Advanced Solid Tumor
Refractory AML
Interventions
First Posted Date
2022-02-07
Last Posted Date
2023-07-27
Lead Sponsor
New Epsilon Innovation Limited
Target Recruit Count
24
Registration Number
NCT05226468
Locations
🇭🇰

The University of Hong Kong Phase I Clinical Trials Centre, Hong Kong, Hong Kong

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.